The Key to Success is in Our People

Our team is comprised of true innovators in the field who are passionate about changing the way we treat GI diseases. 



Mark McKenna

President & CEO, Board Member

Mr. McKenna serves as President, CEO and member of the board of Prometheus Biosciences. Prior to joining Prometheus Biosciences, Mr. McKenna was President & CEO of Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies.  He joined Salix in March 2016 as the Senior Vice President and General Manager, responsible for the company’s gastrointestinal franchise. During his tenure, Mr. McKenna successfully led the company through a series of key strategic acquisitions, the launch of a number of new products, and delivered strong operating performance, with revenue increasing from $1.2B to $2B. Prior to joining Salix, Mr. McKenna spent more than a decade with Bausch + Lomb, most recently as Senior Vice President/General Manager of its U.S. Vision Care business.  Prior to Bausch + Lomb, Mark held several roles of increasing responsibility at Johnson & Johnson.  Mark holds a B.S. in Marketing from Arizona State University, an MBA from Azusa Pacific University and is a Fellow with the University of Pennsylvania, Wharton School of Business. 


Laurens Kruidenier, PhD

Chief Scientific Officer

Dr. Kruidenier has been active in pre-clinical GI research for over 20 years. Prior to joining Prometheus Biosciences, Laurens was VP of Discovery at Second Genome, where he was responsible for a portfolio of microbiome programs. Previously, Laurens held various positions at GlaxoSmithKline and at Takeda Pharmaceuticals, where he was Head of GI Immunology Research. Laurens received his PhD in Experimental Gastroenterology from Leiden University (The Netherlands), after which he continued his training in GI immunology as a post-doctoral fellow at the University of London. Over the years, his research has resulted in multiple publications in top scientific journals, including Gastroenterology, Nature and Nature Chemical Biology.


Allison Luo, MD

Chief Medical Officer

Dr. Luo has served as Chief Medical Officer of Precision IBD, the predecessor of Prometheus Biosciences since August 2018. Prior to joining Prometheus Biosciences, Dr. Luo was Senior Vice President of Clinical Development for Gastroenterology at Progenity, and Vice President of Clinical Development at Ophthotech where she was responsible for the completion of two Phase 3 studies. Prior to Ophthotech, Dr. Luo was Executive Director at Bristol-Myers Squibb where she was responsible for Inflammatory Bowel Disease and led the Phase 3 program for Orencia (abatacept) and the Phase 2 program for eldelumab (anti-IP10 antibody) for ulcerative colitis and Crohn’s disease. Earlier in her career she was a Medical Director at Abbott Laboratories where she led the regulatory filing of Humira for rheumatoid arthritis in Japan and developed the clinical trial protocols for Humira in ulcerative colitis. Dr. Luo received her Bachelor of Science in Biochemistry and Doctor of Medicine degrees from Northwestern University, followed by a residency in internal medicine at Loyola University, and a fellowship in drug development at Abbott Laboratories (Abbvie).


Keith W. Marshall, PhD

Chief Financial Officer

Dr. Marshall was appointed as our Chief Financial Officer in August 2020.  Prior to joining Prometheus, Dr. Marshall served as Executive Vice President, Chief Operating Officer and Chief Financial Officer of Conatus Pharmaceuticals (Nasdaq: CNAT) since 2017.  Prior to Conatus, he served as Chief Financial Officer and Head of Corporate Development  at Torque Therapeutics (now Repertoire Immune Medicines), a Flagship Pioneering company.  Dr. Marshall also served as Managing Director in Healthcare Investment Banking at GCA Savvian Advisors, Managing Director, Co-founder, and Chief Financial Officer at Montgomery, Marshall Healthcare Partners, and Managing Director of Healthcare Investment Banking at Montgomery & Co. He began his career in investment banking at JP Morgan.  Dr. Marshall holds an MBA from the University of Chicago – Booth School of Business, a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco and an A.B. in Biology from Washington University in St. Louis.


Olivier Laurent, PhD

Chief Technology Officer

Dr. Laurent joined Prometheus in September 2020 as Chief Technology Officer.  Dr. Laurent most recently served as Chief Scientific Officer at Intrepida Bio, an immuno-oncology company focused on developing novel antibodies for the treatment of solid tumors.  Prior to this position, Dr. Laurent spent twenty years designing and developing biopharmaceuticals at companies including Sanofi, Bayer HealthCare, Genentech, Pfizer, CovX (acquired by Pfizer in 2008) and Ambrx (acquired by a Chinese consortium in 2015). Dr. Laurent holds numerous patents in the field of biotherapeutics and has contributed to multiple antibody regulatory dossiers. Dr. Laurent holds a Ph.D. in Cell Biology from the University of Grenoble in France and is an alumnus of the École Normale Supérieure de Lyon.


Mark Stenhouse

Chief Operating Officer

Mr. Stenhouse joined Prometheus Biosciences as our Chief Operating Officer in March 2021. Prior to joining Prometheus Biosciences, Mr. Stenhouse served as General Manager of the Screening Business Unit at Exact Sciences. Prior to Exact Sciences, he spent 27 years at AbbVie/Abbott serving most recently as Vice President, US Immunology, from October 2016 until March 2018. Prior to leading the US Immunology business, he served as Vice President and General Manager of the Gastroenterology franchise having spent 10 years working in Inflammatory Bowel Disease.  Mr. Stenhouse currently serves as a member of the Board of Directors for Phathom Pharmaceuticals. He earned a BS in business from the College of Charleston.


Timothy K. Andrews

General Counsel

Timothy K. Andrews has served as our General Counsel and Secretary since November 2020. From 2016 through 2019 he served as General Counsel and Secretary for Sienna Biopharmaceuticals, Inc., a publicly traded, clinical-stage biotech company, where he was instrumental in acquiring the company’s core assets, planning and executing its IPO, and building the legal function and corporate governance systems. Mr. Andrews served as Senior Corporate Counsel and Assistant Secretary at Allergan, Inc. from 2011 through 2015, when the company was acquired by Actavis plc. At Allergan, Inc., he had legal responsibility for U.S. and international business development transactions, including acquisitions, licensing and partnerships, as well as corporate governance and securities law compliance. From 2006 to 2011, Mr. Andrews was a corporate attorney at Latham & Watkins LLP, where his practice focused on public company representation, mergers and acquisitions and corporate finance, serving clients in the life sciences sector, including Allergan. He was previously a Business Analyst at Deloitte Consulting. Mr. Andrews received a B.A. in Political Economy from the University of California, Berkeley and a J.D. from Loyola Law School, Los Angeles.


Chris Doughty

Chief Business Officer

Mr. Doughty joined Prometheus Biosciences as Senior Vice President of Corporate Development in February 2021.  Chris joined Prometheus from Strata Oncology, a precision oncology company, where he served as Vice President of Strategy and Business Development and led the organization’s pharma business development efforts.   Before pursuing opportunities focused in precision medicine, Chris began his career in strategy consulting, most recently serving as an Engagement Manager at McKinsey & Company and also having spent time at Kaufman Hall and Deloitte. Chris holds an MBA from the University of Michigan’s Ross School of Business and a B.S.E in Industrial & Operations Engineering from the College of Engineering at the University of Michigan.


Noël Kurdi

Vice President of Investor Relations and Communications

Noël Kurdi joined Prometheus Biosciences as Vice President of Investor Relations and Communications for Prometheus in February 2021. Most recently, Ms. Kurdi served as the head of Investor Relations for BiomX and Nanobiotix, where she instituted a global investor relations and communications platform, and played an instrumental role in multiple capital raising initiatives. She also served as VP at Solebury Trout Group, a life sciences IR and Corporate Strategy advisory provider. Earlier, Noël held roles of increasing responsibility in healthcare equity research and sales, investor relations, and business development. Noël holds an MBA in Finance and Marketing from the Fordham Graduate School of Business and a BBA in International Business and Marketing from George Washington University. She is a member of the National Investor Relations Institute and won the IR Magazine People’s Choice Award in 2017. 


Evan McClure, MD, MBA

Chief of Staff & VP, Business Operations

Dr. McClure joined Prometheus Biosciences as Chief of Staff & Vice President, Business Operations in January 2021. Prior, he spent five years in executive search, recruiting C-suite and board leaders to biotechnology and healthcare companies in the Americas, Europe, and Asia. Earlier, Evan founded and led a life sciences strategy consultancy, worked in Genentech’s Market Analysis and Strategy group, founded a nonprofit organization supporting healthcare entrepreneurship, and advised venture capital and private equity firms investing in health technologies. He earned his MD from Emory University School of Medicine, where he led a seminar in biomedical entrepreneurship. He also earned an MBA with concentrations in Strategy and Finance from Emory’s Goizueta Business School and an undergraduate degree in Neuroscience and Medical Sociology from Vanderbilt University. 


Vika Brough

Senior Vice President, Finance

Ms. Brough has over fifteen years of experience in public and private accounting roles. She started her career as an auditor at Ernst & Young Assurance practice in San Diego, California.  During the ten years as an auditor, Ms. Brough served many multinational public and private clients in life science, medical devices and technology industries.  After Ernst & Young, Ms. Brough was Head of Finance at Human Longevity, Inc., a genomics-based company in San Diego, where she oversaw financial planning, accounting, treasury and procurement functions. Ms. Brough graduated from the San Diego State University with a Bachelor of Accounting degree.


Nori Ebersole

Chief People Officer

Ms. Nori Ebersole serves as Chief People Officer since April 2021. Prior to joining Prometheus Biosciences, Ms. Ebersole served as EVP & Chief Human Resources Officer for Urovant Sciences, Inc (Nasdaq; UROV) from 2017 to 2021, until its $681M enterprise value take private merger with Sumitomo Dainippon at a 96% premium. In this role, she was instrumental in their 2018 IPO, building the board, executive and senior leadership teams. She also led the development and execution of their diversity, equity and inclusion strategy, employment brand, talent acquisition, mission, vision and values strategies and the build of the field sales and market access teams for commercial launch. Prior to Urovant, she was the Chief Human Resources Officer at Paul Hastings, LLP from 2015 to 2017. Ms. Ebersole also served 18 years at Allergan Inc, from 1994 to 2015, until their sale to Actavis for $70.5B. Ms. Ebersole earned a B.S. in Business Administration from the University of Southern California Marshall School of Business and serves on the board of Big Brothers, Big Sisters of Orange County.